Insurers' margins on individual insurance plans improved in aggregate in 2016 over 2015. But their losses still totaled billions of dollars.
Shareholders of the embattled drugmaker Mylan voted to re-elect its board members at a meeting Thursday morning, despite pressure to oust select executives amid widespread backlash for the skyrocketing price of EpiPens.
Hospitals are taking advantage of favorable borrowing rates to raise money in the bond markets for acquisitions and debt refinancing. But will they lament the binge?
Hospital stock prices jumped on Thursday as investors reacted to the Senate's proposal for repealing and replacing the Affordable Care Act.
WellStar Health System and Sutter Health continue the parade of not-for-profits raising money in the bond markets with separate proposed offerings totaling about $1.3 billion.
DuPage Medical Group, the largest independent physician group in the Chicago area, is continuing its rapid expansion by entering the northwest suburbs.
The fragmented ophthalmology and eye-care medical practice sector has become a new target for private equity investors.
The deal comes months after Teladoc reported full-year losses for 2016.
As its former CEO, Dr. Michael Genord, oversaw the effort to turn around the financial and operational health of Flint-based insurer HealthPlus of Michigan before the commercial and Medicare business was sold to Health Alliance Plan. As CEO of HAP Midwest Health Plan, Genord was again a key player.
Hospital mergers like the one that formed eight-hospital Beaumont Health in September 2014 often take five years or more to ultimately be judged a success or failure.
Henry Ford Health System had a big year in 2016 when it added Jackson-based Allegiance Health in April and Flint-based HealthPlus of Michigan earlier in February. The two acquisitions added about $800 million in annual revenue to the now $5.7 billion system.
Making actual generic drug acquisition costs available to third-party payers would empower health plans to negotiate lower rates and essentially level the playing field in a pharmaceutical supply chain that's shrouded in secrecy, according to a new paper.